UBS Group AG Sells 44,656 Shares of Establishment Labs Holdings Inc. $ESTA

UBS Group AG lessened its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 51.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 41,389 shares of the company’s stock after selling 44,656 shares during the period. UBS Group AG’s holdings in Establishment Labs were worth $3,016,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ESTA. Quarry LP bought a new position in Establishment Labs during the 3rd quarter valued at approximately $34,000. State of Wyoming bought a new position in Establishment Labs during the 3rd quarter valued at approximately $71,000. Osaic Holdings Inc. increased its position in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares in the last quarter. PharVision Advisers LLC bought a new position in Establishment Labs during the 3rd quarter valued at approximately $203,000. Finally, Choreo LLC bought a new position in Establishment Labs during the 4th quarter valued at approximately $204,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA opened at $72.19 on Tuesday. The business’s fifty day simple moving average is $64.76 and its two-hundred day simple moving average is $68.24. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $83.31. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -48.45 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the prior year, the business posted ($0.70) earnings per share. The business’s revenue for the quarter was up 44.7% on a year-over-year basis. Research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 330,000 shares of company stock worth $22,854,538. Company insiders own 9.99% of the company’s stock.

Analysts Set New Price Targets

ESTA has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Stephens raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Mizuho raised their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, BTIG Research raised their price objective on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Establishment Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.